A Phase III, Randomized, Double-Blind Study of Torivumab Plus Chemotherapy Versus Placebo Plus Chemotherapy in Previously Untreated Advanced Non-Small Cell Lung Cancer · Phase III
SITE009 (AUS) · Dr. Novak
consented 2022-08-06
AEs
3
Serious
0
Dropout signal
–
Adverse events
mild
assessed
Grade 1 Stomatitis — outcome: UNKNOWN; onset 2022-11-12 (study day 78); relationship: N
mild
assessed
Grade 1 Fatigue — outcome: RECOVERED/RESOLVED; onset 2022-11-20 (study day 86); relationship: not assessed
mild
assessed
Grade 1 Thrombocytopenia — outcome: RECOVERED/RESOLVED; onset 2023-01-20 (study day 147); relationship: N
Data queries
No data queries.